	US 11,957,754 B2
	Clinical formulations
Roger Gay, Acton, MA (US); Judson Ratliff, Harvard, MA (US); and Romma E. Southwick, Waban, MA (US)
Assigned to Astellas Institute for Regenerative Medicine, Westborough, MA (US)
Filed by Astellas Institute for Regenerative Medicine, Westborough, MA (US)
Filed on Mar. 23, 2021, as Appl. No. 17/210,448.
Application 17/210,448 is a division of application No. 15/753,232, granted, now 11,013,808, previously published as PCT/US2016/047545, filed on Aug. 18, 2016.
Claims priority of provisional application 62/206,821, filed on Aug. 18, 2015.
Prior Publication US 2021/0275673 A1, Sep. 9, 2021
Int. Cl. A61K 47/26 (2006.01); A61K 9/08 (2006.01); A61K 31/7004 (2006.01); A61K 31/728 (2006.01); A61K 33/06 (2006.01); A61K 33/14 (2006.01); A61K 35/28 (2015.01); A61K 35/30 (2015.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/36 (2006.01); A61P 27/02 (2006.01)

CPC A61K 47/26 (2013.01) [A61K 9/08 (2013.01); A61K 31/7004 (2013.01); A61K 31/728 (2013.01); A61K 33/06 (2013.01); A61K 33/14 (2013.01); A61K 35/28 (2013.01); A61K 35/30 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/36 (2013.01); A61P 27/02 (2018.01)]

29 Claims

1. A method for treating a retinal disease, the method comprising

administering, to the eye of a human subject having a retinal disease, an effective amount of a pharmaceutical composition comprising

(a) a population of cells, and

(b) a solution comprising

(i) about 0.1-1.2 mM CaCl₂, about 0.05-5 mM MgCl₂, about 1-2.5 mM KCl, about 0.5-2 mM sodium citrate, about 15-17 mM dextrose, and about 125-175 mM NaCl, or

(ii) about 0.5-0.9 mM CaCl₂, about 0.2-0.4 mM MgCl₂, about 1.6-2.4 mM KCl, about 0.8-1.2 mM sodium citrate, about 13-19 mM dextrose, and about 116-174 mM NaCl, or

(iii) about 0.008-0.012% CaCl₂dihydrate, about 0.0048-0.0072% MgCl₂hexahydrate, about 0.012-0.018% KCl, about 0.028-0.042% sodium citrate dihydrate, about 0.23-0.35% dextrose, and about 0.68-1.02% NaCl.